ID: ALA4747369

Max Phase: Preclinical

Molecular Formula: C43H46ClN7O6

Molecular Weight: 792.34

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  CC1(C)[C@H](NC(=O)c2ccc(N3CCN(CC4CN(c5ccc6c(c5)C(=O)N(C5CCC(=O)NC5=O)C6=O)C4)CC3)cc2)C(C)(C)[C@H]1Oc1ccc(C#N)c(Cl)c1

Standard InChI:  InChI=1S/C43H46ClN7O6/c1-42(2)40(43(3,4)41(42)57-30-11-7-27(21-45)33(44)20-30)47-36(53)26-5-8-28(9-6-26)49-17-15-48(16-18-49)22-25-23-50(24-25)29-10-12-31-32(19-29)39(56)51(38(31)55)34-13-14-35(52)46-37(34)54/h5-12,19-20,25,34,40-41H,13-18,22-24H2,1-4H3,(H,47,53)(H,46,52,54)/t34?,40-,41-

Standard InChI Key:  NYTQWRHXSYHGSP-RPINAMIVSA-N

Associated Targets(Human)

VHL/Androgen receptor 497 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

VCaP 1078 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

LNCaP 8286 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 792.34Molecular Weight (Monoisotopic): 791.3198AlogP: 4.48#Rotatable Bonds: 9
Polar Surface Area: 155.39Molecular Species: NEUTRALHBA: 10HBD: 2
#RO5 Violations: 1HBA (Lipinski): 13HBD (Lipinski): 2#RO5 Violations (Lipinski): 2
CX Acidic pKa: 11.59CX Basic pKa: 8.03CX LogP: 4.95CX LogD: 4.23
Aromatic Rings: 3Heavy Atoms: 57QED Weighted: 0.30Np Likeness Score: -0.81

References

1. Kargbo RB.  (2021)  Androgen Receptor Degradation for Therapeutic Intervention of Prostate Cancer Drug Resistance.,  12  (4.0): [PMID:33859784] [10.1021/acsmedchemlett.1c00120]
2. Han X, Zhao L, Xiang W, Qin C, Miao B, McEachern D, Wang Y, Metwally H, Wang L, Matvekas A, Wen B, Sun D, Wang S..  (2021)  Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer.,  64  (17.0): [PMID:34431670] [10.1021/acs.jmedchem.1c00882]
3. Kargbo RB..  (2022)  Targeted Degradation of Androgen Receptor for the Potential Treatment of Prostate Cancer.,  13  (10.0): [PMID:36267135] [10.1021/acsmedchemlett.2c00415]

Source